Copies of letters sent to UK healthcare professionals in August 2012, to inform of new safety information and advice include:

Date sent Medicine Safety information
6 August 2012 OndansetronPDF file (opens in new window) (262Kb) QTC prolongation – new dose restriction for intravenous ondansetron given for chemotherapy-induced nausea and vomiting in adults
22 August 2012 TamifluPDF file (opens in new window) (322Kb) Concentration of oral suspension to be changed from 12 mg/mL to 6 mg/mL
24 August 2012 DepocytePDF file (opens in new window) (203Kb) Possible risk of sterility failure at manufacturing site – product recall in Europe
28 August 2012 CalcitoninPDF file (opens in new window) (397Kb) Increased risk of malignancies with the long-term use of calcitonin. Calcitonin should no longer be used in the treatment of osteoporosis.









Posted on the UK MHRA website on 31 August 2012